NCI Broadens the Pool of Oncologists Enrolling Patients in Phase III Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

BETHESDA, Md-To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

BETHESDA, Md—To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

Under EPP, qualified oncologists can enter patients in 16 large clinical trials for breast, lung, prostate, and colorectal cancer. Other phase III trials will be opened up to EPP participating physicians later this year.

The program offers a simplified, Internet-based process for enrolling patients and a direct reimbursement of $1,500 per patient to physicians to cover their research-related time and costs.

NCI expects EPP to become a national program that will significantly reduce the time it takes to accrue the hundreds or thousands of patients necessary for phase III studies. Additional information is available on the EPP website located at http://light.emmes.com/epp

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.